Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 26, 2022; 10(33): 12268-12277
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12268
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12268
Table 1 Laboratory data at admission
Laboratory parameter | Result | Normal range |
WBC (/μL) | 11590 | 4000-10000 |
Neutrophil (%) | 58.7 | 40-80 |
Lymphocyte (%) | 31.2 | 25-50 |
Monocyte (%) | 9.8 | 0-9 |
Eosinophil (%) | 0.1 | 0-7 |
Basophil (%) | 0.2 | 0-1.8 |
Platelet (/μL) | 38000 | 150000-400000 |
AST (U/L) | 242 | 5-40 |
ALT (U/L) | 73.5 | 5-40 |
Total bilirubin (mg/dL) | 6.5 | 0.2-1.2 |
CRP (mg/dL) | > 16 | 0.0-0.3 |
Table 2 Infectious disease diagnostic test results
Diseases | Result |
COVID-19 | Negative |
Ebstein-Barr virus | Negative |
Cytomegalovirus | Negative |
Hepatitis A | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Hantavirus | Negative |
HIV | Negative |
Rickettsia tsutsugamushi | Negative |
Leptospira | Negative |
Blood bacterial culture | Negative |
Urine bacterial culture | Negative |
Table 3 Evaluation of autoimmune hepatitis
Laboratory parameter | Results | Normal range |
Anti LKM-1 Ab | Negative | Negative |
Anti-mitochondria Ab | Negative | Negative |
ANA (titer) | Centromere 1:1280 | |
Anti dsDNA antibody (IU/mL) | Negative < 10 | 10-15 |
p-ANCA (IU/mL) | Negative < 0.1 | 0-3.5 |
Table 4 Hematologic adverse events except for thrombocytopenic syndrome
Types of hematologic adverse events | Patient No. and Ref. | Age, yr | Sex | Symptom onset (No. of days after vaccination) | Symptoms | Underlying diseases | Type of vaccine | Outcome |
ITP | 1, Tarawneh and Tarawneh[31] | 22 | M | 3 | Petechia, gum bleeding | None | Pfizer | Recovery |
2-9, Lee et al[26] | NA | NA | NA | NA | NA | Pfizer | NA | |
10-20, Lee et al[26] | NA | NA | NA | NA | NA | Moderna | NA | |
21, Shah et al[27] | 53 | M | 8 | Petechia rash, myalgia | Crohn’s disease | Pfizer | Recovery | |
22, Shah et al[27] | 67 | M | 2 | Melena | Chronic ITP | Pfizer | Recovery | |
23, Shah et al[27] | 59 | F | 2 | Bloody diarrhea | SLE, chronic ITP | J&J | Recovery | |
24, Ganzel and Ben-Chetrit[25] | 53 | M | 14 | Epistaxis | DM, HTN, otitis | Pfizer | Recovery | |
25, Toom et al[32] | 36 | F | 14 | Petechia, bruising, gum bleeding, headache | ITP | Moderna | Recovery | |
26, Paulsen et al[28] | 72 | M | 11 | Petechia, epistaxis, headache | Autoimmune thyroiditis | AZD1222 | NA | |
27 Paulsen et al[28] | 71 | F | 11 | Petechia, hyposphagma | Latent hyperthyroidism, breast cancer, stroke | AZD1222 | NA | |
28 Paulsen et al[28] | 66 | M | 2 | Petechia | HTN, mild thrombocytopenia | AZD1222 | NA | |
29 Paulsen et al[28] | 64 | F | 15 | None | HTN, COPD, steatosis hepatitis | AZD1222 | NA | |
30, Ghosh et al[33] | 63 | F | 2 | Bruise | COPD, Type 2 DM | Pfizer | Recovery | |
AIHA | 30, Gaignard et al[13] | 56 | M | 3 | Painless petechia | Evans syndrome | Moderna | Recovery |
31, Gaignard et al[13] | 77 | M | 5 | Weakness, fatigue, shortness of breath | none | Moderna | Recovery | |
32, Murdych[16] | 84 | M | 19 | Urinary frequency, dizziness | Prostate & colon cancer, CAD, HTN, trace cryoglobulinemia, emphysema, mild chronic anemia, major depression and/or anxiety | Pfizer | Recovery | |
33, Brito et al[24] | 88 | F | 2 | Asthenia, jaundice | Insomnia | mRNA vaccine | Recovery | |
Hemolytic crisis | 35, Pérez-Lamas et al[15] | 57 | F | 2 | Chills, weakness, exertional dyspnea, jaundice, mild hemoglobinurina | Cold agglutinin disease | mRNA vaccine | Recovery |
Hemolysis | 36, Gerber et al[14] | 25 | M | 5 | Abdominal pain | PNH | Pfizer | NA |
37, Gerber et al[14] | 45 | M | 0 | Fever, headache, myalgia, fatigue, hemoglobinuria | PNH | Pfizer | NA | |
37, Gerber et al[14] | 32 | F | 0 | Fever, rigor | PNH | Moderna | NA | |
38, Gerber et al[14] | 63 | M | 0 | Fatigue, darkening urine | PNH | Moderna | NA |
- Citation: Lee SB, Park CY, Park SG, Lee HJ. Case mistaken for leukemia after mRNA COVID-19 vaccine administration: A case report. World J Clin Cases 2022; 10(33): 12268-12277
- URL: https://www.wjgnet.com/2307-8960/full/v10/i33/12268.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i33.12268